GH / IGF-1 Secretagogues: Tissue Regeneration vs. Oncogenic Proliferation Risk
Growth hormone secretagogues (such as Sermorelin, Ipamorelin, and CJC-1295) restore youthful GH pulsatility and accelerate tissue repair, but elevating systemic IGF-1 may accelerate neoplastic transformation and shorten longevity.
Position A: Therapeutic Regenerative Use (Pulsed Secretagogues)
Camp ADr. Gregory Fahy
Intervene Immune (TRIIM Trial PI)
Physiologic growth hormone administration reverses thymic involution, regenerates the immune repertoire, and systematically reverses epigenetic age by 2.5 years (TRIIM trial). When paired with DHEA and metformin to counteract insulin resistance, growth hormone signaling restores critical regenerative capacity without elevating long-term cancer incidence.
Position B: Contraindicated for Longevity (Laron Dwarfism Model)
Camp BDr. Andrzej Bartke
Southern Illinois University School of Medicine
Across all mammalian models—from Ames and Snell dwarf mice to GHR knockout mice and human Laron syndrome cohorts—downregulation of the GH/IGF-1 axis is the most reproducible genetic mechanism for extended lifespan and near-total protection from cancer and diabetes. Artificially elevating GH/IGF-1 trades short-term physical vigor for long-term neoplastic risk.